Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab versus placebo plus rituximab in untreated follicular lymphoma
NL-OMON59749Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing Ibrutinib + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Oct 2017; status: completed.
02
Drugs
ibrutinibrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON59749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59749.